Jefferies Financial Group Inc. Makes New $237,000 Investment in Applied Therapeutics, Inc. (NASDAQ:APLT)

Jefferies Financial Group Inc. purchased a new position in Applied Therapeutics, Inc. (NASDAQ:APLT) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 276,700 shares of the company’s stock, valued at approximately $237,000.

A number of other hedge funds have also modified their holdings of the company. Ground Swell Capital LLC bought a new position in shares of Applied Therapeutics in the fourth quarter worth approximately $27,000. Deutsche Bank AG boosted its position in shares of Applied Therapeutics by 0.7% in the fourth quarter. Deutsche Bank AG now owns 4,468,122 shares of the company’s stock worth $3,843,000 after purchasing an additional 30,520 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Applied Therapeutics by 29.1% in the fourth quarter. BNP Paribas Financial Markets now owns 174,651 shares of the company’s stock worth $150,000 after purchasing an additional 39,379 shares during the period. Alyeska Investment Group L.P. boosted its position in shares of Applied Therapeutics by 175.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,707,497 shares of the company’s stock worth $2,318,000 after purchasing an additional 1,725,824 shares during the period. Finally, Schonfeld Strategic Advisors LLC boosted its position in shares of Applied Therapeutics by 2,458.3% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 8,762,291 shares of the company’s stock worth $7,502,000 after purchasing an additional 8,419,781 shares during the period. 98.31% of the stock is currently owned by institutional investors.

Applied Therapeutics Stock Performance

Shares of NASDAQ:APLT opened at $0.60 on Friday. The firm has a fifty day moving average price of $0.43 and a 200 day moving average price of $1.91. Applied Therapeutics, Inc. has a fifty-two week low of $0.30 and a fifty-two week high of $10.62. The firm has a market cap of $85.36 million, a price-to-earnings ratio of -0.37 and a beta of 2.00.

Applied Therapeutics (NASDAQ:APLT) last issued its earnings results on Monday, April 14th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.61 million. As a group, research analysts predict that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Royal Bank of Canada reiterated a “sector perform” rating and issued a $1.50 price target on shares of Applied Therapeutics in a research report on Wednesday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.